ALFA Filings
Every announcement, straight from the exchange
Every AstraZeneca Pharma India results update announcement on NSE and BSE, newest first, each with its own page.
Time
3 announcements
AstraZeneca Pharma India reported 30% growth in Q2 results, with three new regulatory approvals. It also announced MoUs with two state governments.
AstraZeneca reported 30% revenue growth to ₹682.8 Crore in Q1 FY2026-27, driven by strong performance across its core Oncology and Biopharmaceutical therapy areas.
AstraZeneca Pharma India reported FY 2025-26 revenue of ₹2,275.58 Crore, marking 33% growth. The Company secured 11 regulatory approvals, reinforcing leadership in oncology and biopharmaceuticals.